Degarelix
FDA-approved GnRH (the brain's master reproductive-hormone signal) medicines that block a signal for prostate cancer (Firmagon).
What it's for
Degarelix is a long-acting GnRH (the brain's master reproductive-hormone signal) medicines that block a signal used in androgen-deprivation therapy.
What it does for the body
Treats advanced prostate cancer by rapidly suppressing testosterone without the flare seen with GnRH (the brain's master reproductive-hormone signal) medicines (brain signals that control reproductive hormones). People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
GnRH (the brain's master reproductive-hormone signal) receptors (lock-and-key landing spots on cells) blockade lowers LH/FSH, collapsing testicular testosterone production. These act on the body's reproductive-hormone control loop — like adjusting the master switch that tells the ovaries or testes what to do.
Research context
Bottom line for readers: Degarelix has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Sexual research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Degarelix — FDA.gov search
- ClinicalTrials.gov search: Degarelix — U.S. clinical trials registry
- Drugs@FDA search: Degarelix — FDA drug database (if approved)
- PubMed search: Degarelix — NCBI PubMed
- PubMed Central search: Degarelix — NCBI PMC